Your search for rivaroxaban returned 143 results

Your search for rivaroxaban returned 143 results

Sort Results:

Relevant Recent
News

Bleeding Outcomes for Elderly NVAF Patients on Xarelto Announced

New data presented at the American Geriatrics Society 2015 Annual Scientific meeting suggests that the rates of major bleeding and fatal outcomes in elderly patients with non-valvular atrial fibrillation (NVAF) treated with Xarelto (rivaroxaban; Janssen) are consistent with those reported in Phase 3 clinical trials.
Drugs in the Pipeline

Xarelto sNDA Submitted for Two New Vascular Indications

For this group the risk of stroke was reduced by 42% (HR 0.58; 95% CI, 0.44-0.76; P<0.001), CV death by 22% (HR 0.78; 95% CI, 0.64-0.96; P=0.02) and heart attack by 14% (HR 0.86; 95% CI, 0.70-1.05; P=0.14).
News

Real-World Post-Marketing Safety Data for Xarelto Presented

The post-marketing safety profile of Xarelto (rivaroxaban; Janssen) was consistent with the findings seen in the Phase 3 study, ROCKET AF, that supported the approval for Xarelto in the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF).
Clinical Charts

Thromboembolic Disorder Assessment: DVT/PE

Risk factors, prevention strategies, signs & symptoms, and general treatment options for deep vein thrombosis (DVT) and pulmonary embolism (PE).
Drugs in the Pipeline

Eliquis Reversal Agent Demonstrates Efficacy in Phase 3 Study

Portola Pharmaceuticals, Bristol-Myers Squibb Company, and Pfizer announced results from the Phase 3 ANNEXA-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors - Apixaban) study with andexanet alfa as a reversal agent for Eliquis (apixaban).
News

Did Too Much TV Cause This Patient’s DVT?

While death from pulmonary embolism (PE) while watching TV may be a rare event, previous studies have demonstrated a positive association between time watching TV and the risk of death from PE (double the risk for >5hrs per day).